Intrinsic value of Sarepta Therapeutics - SRPT

Previous Close

$131.34

  Intrinsic Value

$2.96

stock screener

  Rating & Target

str. sell

-98%

Previous close

$131.34

 
Intrinsic value

$2.96

 
Up/down potential

-98%

 
Rating

str. sell

We calculate the intrinsic value of SRPT stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 8.6

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  247
  382
  571
  829
  1,170
  1,608
  2,159
  2,835
  3,647
  4,607
  5,721
  6,994
  8,431
  10,031
  11,794
  13,720
  15,804
  18,044
  20,435
  22,976
  25,661
  28,488
  31,455
  34,561
  37,806
  41,189
  44,712
  48,377
  52,189
  56,150
Variable operating expenses, $m
  2,482
  3,834
  5,733
  8,318
  11,735
  16,132
  21,654
  28,432
  36,585
  46,209
  57,379
  70,152
  84,556
  100,605
  118,294
  137,605
  158,509
  180,973
  204,962
  230,438
  257,369
  285,726
  315,487
  346,641
  379,180
  413,111
  448,447
  485,212
  523,439
  563,171
Fixed operating expenses, $m
  228
  233
  238
  243
  249
  254
  260
  265
  271
  277
  283
  290
  296
  302
  309
  316
  323
  330
  337
  345
  352
  360
  368
  376
  384
  393
  401
  410
  419
  428
Total operating expenses, $m
  2,710
  4,067
  5,971
  8,561
  11,984
  16,386
  21,914
  28,697
  36,856
  46,486
  57,662
  70,442
  84,852
  100,907
  118,603
  137,921
  158,832
  181,303
  205,299
  230,783
  257,721
  286,086
  315,855
  347,017
  379,564
  413,504
  448,848
  485,622
  523,858
  563,599
Operating income, $m
  -2,463
  -3,685
  -5,400
  -7,732
  -10,814
  -14,778
  -19,754
  -25,863
  -33,208
  -41,879
  -51,942
  -63,447
  -76,422
  -90,877
  -106,809
  -124,201
  -143,028
  -163,260
  -184,864
  -207,807
  -232,060
  -257,598
  -284,400
  -312,455
  -341,759
  -372,315
  -404,136
  -437,244
  -471,669
  -507,449
EBITDA, $m
  -2,450
  -3,666
  -5,372
  -7,692
  -10,758
  -14,702
  -19,653
  -25,730
  -33,038
  -41,664
  -51,676
  -63,122
  -76,031
  -90,412
  -106,262
  -123,564
  -142,294
  -162,422
  -183,915
  -206,741
  -230,869
  -256,276
  -282,940
  -310,851
  -340,004
  -370,404
  -402,061
  -434,999
  -469,247
  -504,843
Interest expense (income), $m
  2
  23
  20
  33
  51
  77
  110
  153
  206
  272
  352
  445
  554
  678
  818
  975
  1,147
  1,335
  1,538
  1,756
  1,990
  2,238
  2,500
  2,776
  3,065
  3,368
  3,685
  4,015
  4,359
  4,717
  5,089
Earnings before tax, $m
  -2,486
  -3,705
  -5,433
  -7,783
  -10,890
  -14,888
  -19,907
  -26,069
  -33,481
  -42,231
  -52,387
  -64,001
  -77,100
  -91,696
  -107,783
  -125,347
  -144,362
  -164,798
  -186,620
  -209,797
  -234,298
  -260,097
  -287,176
  -315,521
  -345,127
  -376,000
  -408,152
  -441,603
  -476,386
  -512,537
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -2,486
  -3,705
  -5,433
  -7,783
  -10,890
  -14,888
  -19,907
  -26,069
  -33,481
  -42,231
  -52,387
  -64,001
  -77,100
  -91,696
  -107,783
  -125,347
  -144,362
  -164,798
  -186,620
  -209,797
  -234,298
  -260,097
  -287,176
  -315,521
  -345,127
  -376,000
  -408,152
  -441,603
  -476,386
  -512,537

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  497
  767
  1,148
  1,665
  2,349
  3,229
  4,335
  5,692
  7,324
  9,251
  11,488
  14,045
  16,929
  20,142
  23,683
  27,550
  31,735
  36,232
  41,035
  46,136
  51,527
  57,205
  63,163
  69,400
  75,915
  82,708
  89,783
  97,143
  104,797
  112,751
Adjusted assets (=assets-cash), $m
  497
  767
  1,148
  1,665
  2,349
  3,229
  4,335
  5,692
  7,324
  9,251
  11,488
  14,045
  16,929
  20,142
  23,683
  27,550
  31,735
  36,232
  41,035
  46,136
  51,527
  57,205
  63,163
  69,400
  75,915
  82,708
  89,783
  97,143
  104,797
  112,751
Revenue / Adjusted assets
  0.497
  0.498
  0.497
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
  0.498
Average production assets, $m
  73
  113
  170
  246
  347
  478
  641
  842
  1,083
  1,368
  1,699
  2,077
  2,504
  2,979
  3,503
  4,075
  4,694
  5,359
  6,069
  6,824
  7,621
  8,461
  9,342
  10,265
  11,228
  12,233
  13,279
  14,368
  15,500
  16,677
Working capital, $m
  108
  166
  249
  361
  509
  700
  939
  1,233
  1,587
  2,004
  2,489
  3,043
  3,667
  4,363
  5,131
  5,968
  6,875
  7,849
  8,889
  9,994
  11,162
  12,392
  13,683
  15,034
  16,445
  17,917
  19,450
  21,044
  22,702
  24,425
Total debt, $m
  365
  609
  951
  1,417
  2,033
  2,825
  3,820
  5,041
  6,510
  8,245
  10,258
  12,559
  15,154
  18,046
  21,234
  24,713
  28,480
  32,528
  36,850
  41,441
  46,293
  51,403
  56,765
  62,379
  68,242
  74,356
  80,723
  87,348
  94,236
  101,395
Total liabilities, $m
  447
  691
  1,033
  1,499
  2,114
  2,907
  3,901
  5,123
  6,592
  8,326
  10,339
  12,640
  15,236
  18,128
  21,315
  24,795
  28,561
  32,609
  36,932
  41,522
  46,375
  51,484
  56,847
  62,460
  68,324
  74,437
  80,805
  87,429
  94,317
  101,476
Total equity, $m
  50
  77
  115
  167
  235
  323
  433
  569
  732
  925
  1,149
  1,404
  1,693
  2,014
  2,368
  2,755
  3,173
  3,623
  4,104
  4,614
  5,153
  5,720
  6,316
  6,940
  7,592
  8,271
  8,978
  9,714
  10,480
  11,275
Total liabilities and equity, $m
  497
  768
  1,148
  1,666
  2,349
  3,230
  4,334
  5,692
  7,324
  9,251
  11,488
  14,044
  16,929
  20,142
  23,683
  27,550
  31,734
  36,232
  41,036
  46,136
  51,528
  57,204
  63,163
  69,400
  75,916
  82,708
  89,783
  97,143
  104,797
  112,751
Debt-to-equity ratio
  7.360
  7.940
  8.290
  8.510
  8.650
  8.750
  8.810
  8.860
  8.890
  8.910
  8.930
  8.940
  8.950
  8.960
  8.970
  8.970
  8.970
  8.980
  8.980
  8.980
  8.980
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -2,486
  -3,705
  -5,433
  -7,783
  -10,890
  -14,888
  -19,907
  -26,069
  -33,481
  -42,231
  -52,387
  -64,001
  -77,100
  -91,696
  -107,783
  -125,347
  -144,362
  -164,798
  -186,620
  -209,797
  -234,298
  -260,097
  -287,176
  -315,521
  -345,127
  -376,000
  -408,152
  -441,603
  -476,386
  -512,537
Depreciation, amort., depletion, $m
  13
  19
  28
  40
  56
  76
  102
  133
  171
  215
  265
  325
  391
  465
  547
  637
  733
  837
  948
  1,066
  1,191
  1,322
  1,460
  1,604
  1,754
  1,911
  2,075
  2,245
  2,422
  2,606
Funds from operations, $m
  -2,473
  -3,685
  -5,405
  -7,743
  -10,834
  -14,812
  -19,805
  -25,936
  -33,310
  -42,015
  -52,121
  -63,676
  -76,709
  -91,230
  -107,236
  -124,711
  -143,629
  -163,960
  -185,672
  -208,731
  -233,107
  -258,775
  -285,716
  -313,917
  -343,373
  -374,089
  -406,077
  -439,358
  -473,964
  -509,932
Change in working capital, $m
  40
  59
  82
  112
  148
  191
  239
  294
  354
  417
  485
  554
  625
  696
  767
  838
  907
  974
  1,040
  1,105
  1,168
  1,230
  1,291
  1,351
  1,411
  1,472
  1,533
  1,595
  1,658
  1,723
Cash from operations, $m
  -2,513
  -3,744
  -5,487
  -7,856
  -10,983
  -15,002
  -20,045
  -26,230
  -33,664
  -42,433
  -52,606
  -64,230
  -77,333
  -91,926
  -108,003
  -125,548
  -144,536
  -164,935
  -186,712
  -209,836
  -234,275
  -260,005
  -287,007
  -315,268
  -344,784
  -375,560
  -407,609
  -440,953
  -475,622
  -511,655
Maintenance CAPEX, $m
  -7
  -11
  -18
  -27
  -38
  -54
  -75
  -100
  -132
  -169
  -214
  -265
  -325
  -391
  -465
  -547
  -637
  -733
  -837
  -948
  -1,066
  -1,191
  -1,322
  -1,460
  -1,604
  -1,754
  -1,911
  -2,075
  -2,245
  -2,422
New CAPEX, $m
  -27
  -40
  -56
  -77
  -101
  -130
  -164
  -201
  -241
  -285
  -331
  -378
  -427
  -475
  -524
  -572
  -619
  -665
  -710
  -754
  -797
  -840
  -881
  -923
  -964
  -1,005
  -1,046
  -1,089
  -1,132
  -1,177
Cash from investing activities, $m
  -34
  -51
  -74
  -104
  -139
  -184
  -239
  -301
  -373
  -454
  -545
  -643
  -752
  -866
  -989
  -1,119
  -1,256
  -1,398
  -1,547
  -1,702
  -1,863
  -2,031
  -2,203
  -2,383
  -2,568
  -2,759
  -2,957
  -3,164
  -3,377
  -3,599
Free cash flow, $m
  -2,548
  -3,796
  -5,561
  -7,959
  -11,122
  -15,187
  -20,283
  -26,531
  -34,037
  -42,887
  -53,151
  -64,874
  -78,085
  -92,793
  -108,993
  -126,667
  -145,791
  -166,333
  -188,260
  -211,538
  -236,139
  -262,036
  -289,210
  -317,650
  -347,352
  -378,319
  -410,567
  -444,117
  -478,999
  -515,253
Issuance/(repayment) of debt, $m
  -66
  244
  342
  466
  616
  792
  995
  1,221
  1,469
  1,734
  2,013
  2,301
  2,596
  2,892
  3,187
  3,479
  3,767
  4,048
  4,322
  4,590
  4,853
  5,110
  5,363
  5,613
  5,863
  6,114
  6,367
  6,625
  6,888
  7,159
Issuance/(repurchase) of shares, $m
  2,737
  3,732
  5,471
  7,835
  10,959
  14,976
  20,018
  26,205
  33,644
  42,423
  52,611
  64,257
  77,388
  92,017
  108,138
  125,734
  144,781
  165,247
  187,100
  210,307
  234,837
  260,665
  287,772
  316,144
  345,779
  376,679
  408,859
  442,339
  477,151
  513,333
Cash from financing (excl. dividends), $m  
  2,671
  3,976
  5,813
  8,301
  11,575
  15,768
  21,013
  27,426
  35,113
  44,157
  54,624
  66,558
  79,984
  94,909
  111,325
  129,213
  148,548
  169,295
  191,422
  214,897
  239,690
  265,775
  293,135
  321,757
  351,642
  382,793
  415,226
  448,964
  484,039
  520,492
Total cash flow (excl. dividends), $m
  123
  180
  252
  342
  452
  581
  729
  895
  1,076
  1,270
  1,473
  1,684
  1,899
  2,116
  2,332
  2,546
  2,756
  2,962
  3,163
  3,359
  3,551
  3,739
  3,924
  4,108
  4,290
  4,474
  4,659
  4,848
  5,040
  5,239
Retained Cash Flow (-), $m
  -2,737
  -3,732
  -5,471
  -7,835
  -10,959
  -14,976
  -20,018
  -26,205
  -33,644
  -42,423
  -52,611
  -64,257
  -77,388
  -92,017
  -108,138
  -125,734
  -144,781
  -165,247
  -187,100
  -210,307
  -234,837
  -260,665
  -287,772
  -316,144
  -345,779
  -376,679
  -408,859
  -442,339
  -477,151
  -513,333
Prev. year cash balance distribution, $m
  991
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -1,623
  -3,552
  -5,219
  -7,493
  -10,507
  -14,395
  -19,288
  -25,310
  -32,567
  -41,153
  -51,138
  -62,572
  -75,489
  -89,901
  -105,805
  -123,188
  -142,025
  -162,285
  -183,937
  -206,948
  -231,286
  -256,926
  -283,847
  -312,037
  -341,488
  -372,206
  -404,200
  -437,492
  -472,111
  -508,094
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -1,556
  -3,252
  -4,542
  -6,170
  -8,144
  -10,447
  -13,031
  -15,819
  -18,708
  -21,575
  -24,284
  -26,702
  -28,702
  -30,181
  -31,063
  -31,305
  -30,902
  -29,886
  -28,321
  -26,297
  -23,923
  -21,318
  -18,604
  -15,893
  -13,284
  -10,859
  -8,675
  -6,769
  -5,154
  -3,826
Current shareholders' claim on cash, %
  50.0
  5.9
  0.7
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

FINANCIAL RATIOS  of  Sarepta Therapeutics (SRPT)

Valuation Ratios
P/E Ratio -26.9
Price to Sales 1438.4
Price to Book 21.3
Price to Tangible Book
Price to Cash Flow -29.2
Price to Free Cash Flow -28.4
Growth Rates
Sales Growth Rate 400%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 40%
Cap. Spend. - 3 Yr. Gr. Rate 11.8%
Financial Strength
Quick Ratio 32
Current Ratio 0.5
LT Debt to Equity 1.8%
Total Debt to Equity 4.7%
Interest Coverage -133
Management Effectiveness
Return On Assets -75.9%
Ret/ On Assets - 3 Yr. Avg. -66.4%
Return On Total Capital -94.3%
Ret/ On T. Cap. - 3 Yr. Avg. -81.1%
Return On Equity -101.3%
Return On Equity - 3 Yr. Avg. -85.6%
Asset Turnover 0
Profitability Ratios
Gross Margin 100%
Gross Margin - 3 Yr. Avg. 33.3%
EBITDA Margin -5180%
EBITDA Margin - 3 Yr. Avg. -9300%
Operating Margin -5340%
Oper. Margin - 3 Yr. Avg. -9560%
Pre-Tax Margin -5340%
Pre-Tax Margin - 3 Yr. Avg. -9566.7%
Net Profit Margin -5340%
Net Profit Margin - 3 Yr. Avg. -9566.7%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

SRPT stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the SRPT stock intrinsic value calculation we used $154.584 million for the last fiscal year's total revenue generated by Sarepta Therapeutics. The default revenue input number comes from 0001 income statement of Sarepta Therapeutics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our SRPT stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for SRPT is calculated based on our internal credit rating of Sarepta Therapeutics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Sarepta Therapeutics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of SRPT stock the variable cost ratio is equal to 1003.9%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $223 million in the base year in the intrinsic value calculation for SRPT stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Sarepta Therapeutics.

Corporate tax rate of 27% is the nominal tax rate for Sarepta Therapeutics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the SRPT stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for SRPT are equal to 29.7%.

Life of production assets of 6.4 years is the average useful life of capital assets used in Sarepta Therapeutics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for SRPT is equal to 43.5%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $789.217 million for Sarepta Therapeutics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 65.531 million for Sarepta Therapeutics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Sarepta Therapeutics at the current share price and the inputted number of shares is $8.6 billion.

RELATED COMPANIES Price Int.Val. Rating
BCRX BioCryst Pharm 6.87 0.19  str.sell
GILD Gilead Science 72.78 155.76  str.buy
PTCT PTC Therapeuti 38.23 214.00  str.buy
VRTX Vertex Pharmac 177.65 92.21  sell
ALNY Alnylam Pharma 80.01 4.39  str.sell
HEB Hemispherx Bio 0.210 0.04  str.sell
BMRN BioMarin Pharm 99.45 2.96  str.sell
FGEN FibroGen 49.67 2.04  str.sell

COMPANY NEWS

▶ Sarepta CEO charts path forward on Duchenne drug amid stock slide   [Oct-11-18 02:55PM  American City Business Journals]
▶ Square Continues to See Extreme Pressure   [11:11AM  TheStreet.com]
▶ Overall Market Breadth Remains Negative   [Oct-02-18 01:18PM  TheStreet.com]
▶ 5 Best Biotech Stocks to Buy In October   [Oct-01-18 10:28AM  Zacks]
▶ Sarepta investors, analysts shrug off E.U. setback for Duchenne drug   [Sep-21-18 12:01PM  American City Business Journals]
▶ Corrective Action in This Market Is Often Quite Hidden   [Sep-12-18 01:10PM  TheStreet.com]
▶ Six Biotechnology Names on My Watch List   [Sep-10-18 02:17PM  TheStreet.com]
▶ Today's Bell Ringer, September 7, 2018   [09:15AM  CNBC Videos]
▶ Credit Suisse Joins Consensus To Prescribe Sarepta   [Sep-06-18 02:47PM  Benzinga]
▶ The Market Is Finally Pulling Back   [Sep-04-18 01:51PM  TheStreet.com]
▶ CRISPR without consequences? Startup's drug shows promise in animal study   [Aug-30-18 02:00PM  American City Business Journals]
▶ Time to Take Some Profits in Sarepta Therapeutics Stock   [Aug-29-18 05:12PM  InvestorPlace]
▶ Weekly CEO Buys Highlight   [Aug-20-18 11:50AM  GuruFocus.com]
▶ Prepare For the Worst but Stay Positive   [Aug-15-18 02:01PM  TheStreet.com]
▶ Little Fear of Missing Out as Stocks Hold Gains   [Aug-14-18 02:05PM  TheStreet.com]
▶ Overly Aggressive Dip Buyers Finally Trapped   [Aug-13-18 12:36PM  TheStreet.com]
▶ GlycoMimetics Stock Has Substantial Upside   [Aug-10-18 03:17PM  InvestorPlace]
▶ Is Sarepta Therapeutics Stock a Bargain?   [07:52AM  Motley Fool]
▶ Why Sarepta Therapeutics, Inc. Stock Surged Today   [Aug-09-18 05:20PM  Motley Fool]
▶ Sarepta Therapeutics: 2Q Earnings Snapshot   [04:47PM  Associated Press]
▶ The 5 Best Growth Stocks of 2018 (So Far)   [Jul-16-18 02:53PM  Motley Fool]
▶ 3 Gene Therapy Companies In Hot Pursuit Of A 'One-And-Done' Cure   [Jul-13-18 03:35PM  Investor's Business Daily]
▶ [$$] Patients Win With More Access to Treatments   [Jul-08-18 08:30PM  The Wall Street Journal]
▶ Biogen: Let the Situation Cool Off a Bit Before Buying   [Jul-06-18 11:47AM  TheStreet.com]
▶ [$$] A Risky Drug Approval Lesson   [Jul-04-18 08:00PM  The Wall Street Journal]
▶ Unexciting Holiday Trading   [Jul-03-18 11:05AM  TheStreet.com]
▶ Sarepta Therapeutics Could Be Onto Something Big   [Jun-25-18 02:21PM  Motley Fool]
▶ 3 Biotech Stocks That Soared This Week: Are They Buys?   [Jun-23-18 07:15AM  Motley Fool]
▶ Big Biotech Stock Pops and Drops This Week   [Jun-22-18 09:20AM  Motley Fool]
▶ FAANG Stocks Are Being Nailed   [Jun-21-18 11:12AM  TheStreet.com]
▶ Company News For Jun 20, 2018   [10:00AM  Zacks]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.